A new study in the journal Clinical Infectious Diseases looks at the impact of preexposure HIV prophylaxis (PrEP) on lifetime infection risks. “The combination of tenofovir and emtricitabine shows promise as HIV PrEP, taking into account uncertainties regarding efficacy, the risks of developing drug resistance and toxicity, behavioral disinhibition, and drug costs,” note the study authors.
“PrEP could substantially reduce the incidence of HIV transmission in populations at high risk of HIV infection in the United States,” the authors concluded. “Although it is unlikely to confer sufficient benefits to justify the current costs of tenofovir-emtricitabine, price reductions or increases in efficacy could make PrEP a cost-effective option in younger populations or populations at a higher risk of infection. Given recent disappointments in HIV infection prevention and vaccine development, additional study of PrEP-based HIV prevention is warranted.”
Read the rest on HIVPlusMag
No comments:
Post a Comment